Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus docetaxel versus placebo plus docetaxel in previously treated advanced or recurrent non-small cell lung cancer
2007-004803-36Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vargatef plus docetaxel with Placebo plus docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Aug 2008; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004803-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004803-36.